GlobeNewswire Inc.··NaCardiff Oncology's Onvansertib Shows Promise in Overcoming HER2-Low Breast Cancer Resistance
Cardiff Oncology's onvansertib shows preclinical promise in reversing HER2-low breast cancer resistance when combined with trastuzumab deruxtecan; data presentation scheduled for April 2026.
CRDFmetastatic colorectal cancerAACR Annual Meeting 2026